Archived

Study to evaluate the effect of low-intensity pulsed electrical currents on levels of oedema in chronic non-healing wounds Published in Journal of Wound Care, Vol. 20, Iss. 8, 11 Aug 2011,

---

Dr David Chapman-Jones and Mike Ellison attended eProcurement and the NHS Data Challenge, a very interesting conference which helped map the NHS procurement process from the point of view of buying organisations,with presentations from NHS Supply Chain, LPP, Buying Solutions and SBS, and the real challenges faced keeping track of the supplies from purchase to pay (P2P) and the importance of standardising on barcodes were well highlighted by GS1 UK. Synapse will be adopting Global Standard barcodes for all our products.

---

the Accel-Heal® was in attendence at Achieving Healing Despite Extreme Adversity at the National Motorcycle Museum, Birmingham. This was a one-day conference open to all healthcare professionals with an interest in caring for patients with wounds. The day provided delegates with the most up-to-date practice and techniques for the management of many different wound aetiologies. Talks from key opinion leaders from around the world and exhibition stands from the leading suppliers in the Wound Care Sector attracted Tissue Viability and nursing professionals. Accel-Heal® created a lot of interest with several trial enquiries and many leads to follow up.

Accel-Heal was in attendence at the NHS Confederation Annual Conference and Exhibition 2011 at Manchester Central. Attended by Dr David Chapman-Jones, Karen Whitlock and Mike Ellison. The delegate list was from the highest echelons of the Health Service with Trust Chairs, CEOs and Directors attending to listen to Andrew Landsley explaining the future of the NHS and debate in the many plenary and break-out sessions. Although not in our normal “woundcare space”, the exhibition gave us a great opportunity to meet with and explain the benefits that using Accel-Heal® can bring, in terms of improved patient outcome and Trust savings, directly to these industry leaders and decision makers and gain many new leads to follow up.

News

UK-based health technology company Synapse Microcurrent could be supplying its innovative Accel-Heal® wound management system to every NHS Trust in England. It has succeeded in its bid to be appointed onto a national Framework Agreement.

Accel-Heal® builds on the long-established link between electrical current and the body’s healing mechanisms. It is a compact, easily operated device that uses Synapse’s patented micro-current technology to make a real impact in wound management, in particular chronic venous leg ulcers. Accel-Heal® is generally used as a valuable adjunct treatment to compression bandages to significantly accelerate healing and improve patient comfort.

In 2009, independently conducted clinical trials demonstrated that
Accel-Heal® made significant reductions in wound size, exudate levels and pain in 95% of the trial patients who suffered from non-healing venous leg ulcers, with 38% achieving full closure.

The rigorous procurement exercise undertaken by NHS Shared Business Services (NHS SBS) resulted in Synapse Microcurrent being selected to feature on NHS SBS’s 2-year Innovative Wound Healing Technologies Framework Agreement. Over 50 companies competed with only 4 technologies being selected.

Accel-Heal® offered compelling evidence for its innovation, with independent supporting information, including clinical trials and health economics analysis demonstrating a QALY of – (minus) £7,696.

Through the new Framework Agreement NHS Trusts can provide patients with this life-enhancing treatment without further tendering, providing immediate access to the product and saving them time and money. The framework exercise provides assurance that Synapse Microcurrent has been assessed as able to supply products and services that fulfill NHS quality and budgetary needs, and meet all legislative requirements.

John Gildersleeve, CEO of Synapse commented:

“The acceptance of Accel-Heal® on the Framework Agreement is an endorsement not only of this remarkable product, but of the conviction we have demonstrated over a number of years in researching, developing and bringing to market a revolutionary new approach to the treatment of wounds, one that will not only have a dramatic effect on the quality of life for long-suffering chronic would patients, but also on costs.”

Kevin Pritchard, Director of Strategic Sourcing at NHS SBS said:

“The award of this new Framework Agreement realises an ambition for the organisation of partnering with suppliers who provide innovative products and services which deliver genuine advancements in care whilst contributing to cost management. With the estimated annual NHS cost of wound care at approximately £3 billion, any product which can demonstrate clear patient benefits in terms of advanced recovery, cost savings and productivity gains for the NHS is to be applauded.”